Uncategorized
Allergan issues statement on Valeant offer, investor JSP voices concerns
Following various reporting and market speculation, including a letter from Allergan investor Jackson Square Partners, Allergan issued a statement from its board of directors reiterating its stance on the offer by Valeant Pharmaceuticals.“Our conclusion that Valeant’s offer is grossly inadequate and substantially undervalues Allergan remains unchanged,” the company wrote in the statement.